To the Editor The Viewpoint discussing whether it is time for safeguards in the adoption of robotic-assisted surgery1 contains a number of problematic statements. For example, the authors did not mention safeguards already in place, such as the US Food and Drug Administration (FDA), which has reviewed and cleared robotic-assisted surgery as a tool for numerous surgical procedures, including radical and partial nephrectomy, cystectomy, radical prostatectomy, radical hysterectomy, and lobectomy. The FDA has been clear that its recent safety communication regarding breast cancer and other cancers, discussed by the authors, does not change existing clearances for robotic-assisted surgery.2
Curet MJ. Issues in the Adoption of Robotic Surgery. JAMA. 2019;322(14):1413–1414. doi:10.1001/jama.2019.12180
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: